- Trials with a EudraCT protocol (415)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
415 result(s) found for: Pulmonary Hypertension AND Hypertension.
Displaying page 10 of 21.
EudraCT Number: 2004-004928-12 | Sponsor Protocol Number: VICER1 | Start Date*: 2005-03-03 |
Sponsor Name:INO Therapeutics AB | ||
Full Title: A pilot, unicenter, prospective, aleatorized, with parallel groups, controlled and open to evaluate the efficacy of the Nitric Oxide for Inhalation in the prevention of reperfusion in pulmonary donor | ||
Medical condition: pulmonary graft dysfunction | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-003310-17 | Sponsor Protocol Number: AC-063B201 | Start Date*: 2011-11-23 | ||||||||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd. | ||||||||||||||||||
Full Title: "Estudio fase II, multicentrico, doble ciego, randomizado, controlado con placebo para evaluar los efectos de IIoprost inhalado en una prueba de resistencia durante un test de ejercicio cardiopulmo... | ||||||||||||||||||
Medical condition: Hipertension pulmonar secundaria a enfermedad obstructiva pulmonar cronica Pulmonary Hypertension Secondary to Chronic Obstructive Pulmonary Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-003055-60 | Sponsor Protocol Number: RIO-40400 | Start Date*: 2014-10-10 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Evaluation of the pharmacodynamic effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction in a randomized, double blind, placebo controlled, ... | ||
Medical condition: Pulmonary hypertension and heart failure with preserved ejection fraction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-002754-74 | Sponsor Protocol Number: 67896062PAH1013 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:ACTELION Pharmacteuticals Ltd. | |||||||||||||
Full Title: A multicenter, open-label, single-arm study to assess the pharmacokinetics and safety of macitentan in children aged 1 month to <2 years with pulmonary arterial hypertension | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001951-18 | Sponsor Protocol Number: INS1009203 | Start Date*: 2023-03-17 | |||||||||||
Sponsor Name:Insmed Incorporated | |||||||||||||
Full Title: An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term use of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension | |||||||||||||
Medical condition: Participants with Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) DK (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000196-24 | Sponsor Protocol Number: 402-C-1504 | Start Date*: 2016-07-04 |
Sponsor Name:Reata Pharmaceuticals, Inc. | ||
Full Title: A STUDY OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION | ||
Medical condition: Connective Tissue Disease-Associated Pulmonary Arterial Hypertension (WHO Group I CTD-PAH) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) DE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2010-023233-30 | Sponsor Protocol Number: NL33043.029.10 | Start Date*: 2010-12-13 | |||||||||||
Sponsor Name:VU university medical center | |||||||||||||
Full Title: ‘Intravenous iron treatment in iron deficient patients with pulmonary arterial hypertension' | |||||||||||||
Medical condition: Objective: To evaluate the effects of intravenous iron suppletion in iron deficient IPAH patients. Study design: Intervention study Study population: Patients with idiopathic pulmonary arterial hyp... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003610-94 | Sponsor Protocol Number: BAY63-2521/12935 | Start Date*: 2008-11-26 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: Long-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic Pulmonary Arteri... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) SE (Completed) AT (Completed) GB (Completed) IE (Prematurely Ended) BE (Completed) CZ (Completed) DK (Completed) IT (Completed) NL (Prematurely Ended) ES (Prematurely Ended) PT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014453-32 | Sponsor Protocol Number: BPS-MR-PAH-204,Amdt2US,BEL,RO | Start Date*: 2010-01-11 | |||||||||||
Sponsor Name:Lung LLC | |||||||||||||
Full Title: An open-label extension of BPS-MR-PAH-203 in pulmonary arterial hypertension (PAH) patients | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) IE (Completed) DE (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005887-14 | Sponsor Protocol Number: B1321003 | Start Date*: 2010-01-12 | |||||||||||
Sponsor Name:Pfizer Ltd. | |||||||||||||
Full Title: A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF MONOTHERAPY SITAXSENTAN SODIUM VERSUS COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS ... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) SK (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004705-26 | Sponsor Protocol Number: CRO529 | Start Date*: 2007-05-10 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: Safety and Tolerability of Sildenafil in Patients with Eisenmenger Physiology | |||||||||||||
Medical condition: Eisenmenger Syndrome (pulmonary hypertension due to congenital heart disease) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020153-14 | Sponsor Protocol Number: HFpEF | Start Date*: 2011-01-12 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Effects of Sildenafil on pulmonary artery pressure in patients with heart failure with preserved ejection fraction and pulmonary hypertension | ||
Medical condition: The condition to be investigated is isolated left heart failure , also called heart failure with preserved ejection fraction ( HFpEF) with pulmonary hypertension. HFpEF is a clinical syndrome wit... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000667-40 | Sponsor Protocol Number: APD811-003 | Start Date*: 2015-04-23 | |||||||||||
Sponsor Name:Arena Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 2 Trial of APD811, an Oral IP Receptor Agonist, in Patients with Pulmonary Arterial Hypertension | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) ES (Completed) PL (Completed) RO (Ongoing) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001067-36 | Sponsor Protocol Number: 18588 | Start Date*: 2016-11-21 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A prospective, randomized, international, multicenter, double-arm, controlled, open-label study of Riociguat in patients with pulmonary arterial hypertension (PAH) who are on a stable dose of phosp... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) PT (Completed) AT (Completed) CZ (Completed) GB (Completed) DE (Completed) BE (Completed) NL (Completed) DK (Completed) GR (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011150-17 | Sponsor Protocol Number: AMB112565 | Start Date*: 2010-08-26 | |||||||||||
Sponsor Name:GlaxoSmithKline R&D Ltd | |||||||||||||
Full Title: AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension | |||||||||||||
Medical condition: Pulmonary arterial hypotension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) ES (Completed) BE (Completed) SE (Completed) GB (Completed) AT (Completed) GR (Completed) DE (Completed) IT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002988-16 | Sponsor Protocol Number: MINT-2014-01 | Start Date*: 2015-07-01 | |||||||||||
Sponsor Name:Royal College of Surgeons in Ireland | |||||||||||||
Full Title: The Use of Milrinone in Neonates with Persistent Pulmonary Hypertension of the Newborn: A Randomised Controlled Trial Pilot Study (MINT 1) | |||||||||||||
Medical condition: Persistent Pulmonary Hypertension of the Newborn | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001247-39 | Sponsor Protocol Number: CV185-362 | Start Date*: 2017-04-24 | |||||||||||||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||||||||||||
Full Title: A Prospective, Randomized, Open Label, Multi-center Study of the Safety and Pharmacokinetics of Apixaban versus Vitamin K Antagonist or LMWH in Pediatric Subjects with Congenital or Acquired Heart ... | |||||||||||||||||||||||||||||||||
Medical condition: Congenital or Acquired Heart Disease Requiring Chronic Anticoagulation for Thromboembolism Prevention | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) FI (Completed) AT (Completed) ES (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-001411-20 | Sponsor Protocol Number: CQCC374X2201E1 | Start Date*: 2018-01-12 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: Long-term, open label, multicenter, extension study to evaluate the safety and tolerability of QCC374 in patients with PAH | |||||||||||||
Medical condition: Pulmonary arterial hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004328-39 | Sponsor Protocol Number: INFUTER | Start Date*: 2020-04-13 |
Sponsor Name:Fundació Clínic per a la Recerca Biomèdica_FCRB | ||
Full Title: Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal hypertension. A randomised, single blinded clinical trial. | ||
Medical condition: The proposed study aims to investigate the hemodynamic effects of terlipressin and the time profile of these effects in patients with cirrhosis and portal hypertension when given as continuous infu... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-000501-36 | Sponsor Protocol Number: BAY63-2521/18694 | Start Date*: 2016-06-09 | |||||||||||
Sponsor Name:Bayer HealthCare | |||||||||||||
Full Title: An open-label, multi-national, multi-center, single-arm, uncontrolled, long-term extension study of orally administered riociguat in patients with symptomatic pulmonary arterial hypertension (PAH) ... | |||||||||||||
Medical condition: Hypertension, Pulmonary | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
